The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 45 | — | 20.1x | Near average | |
Growth | 53 | 13.4% | 5.6% | Near average | |
Quality | 60 | 269.2% | 7.6% | Near average | |
Safety | 27 | 0.8x | 0.4x | Below average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Ultragenyx Pharmaceutical Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Ultragenyx Pharmaceutical Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Ultragenyx stock shows complete stability in the average price target at $48.36 over the past 30 days, with a consensus from 6 analysts. Despite the steady targets, we observe a wide gap (Dispersion) between the low of $26 and the high of $67, reflecting uncertainty regarding the profitability timeline or upcoming clinical trial results, especially since the current price (23.39) is trading below the lowest analyst expectations.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.